Last reviewed · How we verify
Exposure: COVID-19 severity
At a glance
| Generic name | Exposure: COVID-19 severity |
|---|---|
| Sponsor | Pontificia Universidad Catolica de Chile |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection (NA)
- Incidence, Associated Factors, and Burden of Post COVID-19 Condition in Brazil
- COVID19 and Physical and Emotional Wellbeing of HCP
- Validation of Blood Oxygen Level Test in Well-trained Athletes
- The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign (NA)
- Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging
- PSYCHIATRIC Disorders and Covid-19
- Long-term Neurocognitive and Psychiatric Consequences in Severe COVID-19 Survivors.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exposure: COVID-19 severity CI brief — competitive landscape report
- Exposure: COVID-19 severity updates RSS · CI watch RSS
- Pontificia Universidad Catolica de Chile portfolio CI